Treatment with pramlintide led to a mean reduction in HbA ( 1c ) of 0.67 % from baseline to week 13 that was significantly ( P < 0.0001 ) greater than the placebo reduction ( 0.16 % ) , and a significant placebo-corrected treatment difference was sustained through week 52 ( P = 0.0071 ) .
